162 related articles for article (PubMed ID: 35179064)
41. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
42. Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia.
Iskierka-Jażdżewska E; Robak T
Expert Rev Hematol; 2020 Jan; 13(1):39-53. PubMed ID: 31747803
[No Abstract] [Full Text] [Related]
43. Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far.
Held L; Siu C; Shadman M
Expert Opin Pharmacother; 2021 Apr; 22(6):655-665. PubMed ID: 33645381
[TBL] [Abstract][Full Text] [Related]
44. Venetoclax combined with decitabine induced tumor lysis syndrome in a young patient with acute myeloid leukemia: a case report and literature review.
Zhang H; Liu J; Wu Q; Xia L
Anticancer Drugs; 2024 Jun; 35(5):440-444. PubMed ID: 38386312
[TBL] [Abstract][Full Text] [Related]
45. Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
Freise KJ; Jones AK; Eckert D; Mensing S; Wong SL; Humerickhouse RA; Awni WM; Salem AH
Clin Pharmacokinet; 2017 May; 56(5):515-523. PubMed ID: 27638334
[TBL] [Abstract][Full Text] [Related]
46. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
[TBL] [Abstract][Full Text] [Related]
47. Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Svanberg R; Ostrowski SR; Nasserinejad K; Kersting S; Dobber JA; Mattson M; Tran HTT; Levin MD; Mous R; Kater AP; Niemann CU
Leuk Lymphoma; 2020 Dec; 61(14):3422-3431. PubMed ID: 32865439
[TBL] [Abstract][Full Text] [Related]
48. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Kater AP; Kersting S; van Norden Y; Dubois J; Dobber JA; Mellink CH; Evers LM; Croon-de Boer F; Schreurs J; van der Spek E; Visser H; Idink C; Wittebol S; Hoogendoorn M; Tonino SH; Mobasher M; Levin MD;
Blood Adv; 2018 Dec; 2(24):3566-3571. PubMed ID: 30552161
[TBL] [Abstract][Full Text] [Related]
49. Venetoclax-induced vitiligo in a patient with chronic lymphocytic leukemia.
Abdeen M; Vusqa UT; Asawa P; Felton K; Rinchuse D; Khan C; Samhouri Y; Lister J
Anticancer Drugs; 2022 Nov; 33(10):1167-1170. PubMed ID: 36255070
[TBL] [Abstract][Full Text] [Related]
50. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
51. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
Freise KJ; Hu B; Salem AH
Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
[TBL] [Abstract][Full Text] [Related]
52. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
53. Venetoclax Yields Strong Responses in CLL.
Cancer Discov; 2016 Feb; 6(2):113-4. PubMed ID: 26701089
[TBL] [Abstract][Full Text] [Related]
54. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
Olin JL; Griffiths CL; Smith MB
J Oncol Pharm Pract; 2018 Oct; 24(7):517-524. PubMed ID: 28696175
[TBL] [Abstract][Full Text] [Related]
55. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
Eyre TA; Kirkwood AA; Gohill S; Follows G; Walewska R; Walter H; Cross M; Forconi F; Shah N; Chasty R; Hart A; Broom A; Marr H; Patten PEM; Dann A; Arumainathan A; Munir T; Shankara P; Bloor A; Johnston R; Orchard K; Schuh AH; Fox CP;
Br J Haematol; 2019 May; 185(4):656-669. PubMed ID: 30768675
[TBL] [Abstract][Full Text] [Related]
57. Can Treatment with Venetoclax for Chronic Lymphocytic Leukemia (CLL) Result In Autoimmune Hemolytic Anemia?
Abdel-Samad N; Sughayar R
Am J Case Rep; 2021 Mar; 22():e928514. PubMed ID: 33750754
[TBL] [Abstract][Full Text] [Related]
58. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
[TBL] [Abstract][Full Text] [Related]
59. Venetoclax and obinutuzumab for frontline treatment of chronic lymphocytic leukemia.
Stephens DM
Blood; 2019 Nov; 134(20):1691-1696. PubMed ID: 31488409
[TBL] [Abstract][Full Text] [Related]
60. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
